DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ditropan (Oxybutynin Chloride) - Published Studies

 
 



Ditropan Related Published Studies

Well-designed clinical trials related to Ditropan (Oxybutynin)

A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. [2014]

Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors. [2012]

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011.11]

Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. [2011.02]

[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [2011.01]

Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. [2011.01]

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011]

Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. [2010.07.06]

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. [2010.05]

Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. [2010]

Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. [2009.11]

Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. [2009.10]

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. [2009.04]

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. [2008.09]

Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. [2008.09]

Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review. [2008.07.17]

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. [2008.05]

A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. [2008.05]

Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. [2008.01]

The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin. [2008.01]

Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study. [2008]

Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. [2007.03]

Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. [2007.01]

Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. [2007.01]

The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. [2006.12]

Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. [2006.11]

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. [2006.09]

Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. [2006.06]

A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. [2006.03]

Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. [2006.03]

Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. [2006.02]

Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. [2005.09]

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. [2005.09]

Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial. [2005.09]

Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. [2005.08]

Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. [2005.07]

Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. [2005.05]

Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. [2005.04.01]

Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. [2005]

Well-designed clinical trials possibly related to Ditropan (Oxybutynin)

Which anticholinergic drug for overactive bladder symptoms in adults. [2012]

Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. [2011.11.07]

Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]

Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder. [2011.05]

Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. [2010.08]

Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. [2010.01]

Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. [2009.11]

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. [2009.10.07]

Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment. [2009.07]

Multinational clinical trial in Japan and Korea on detrusitol. [2009.02]

Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial. [2008.11]

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. [2008.11]

The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children. [2008.10]

Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. [2008.05]

A simple validated scale to measure urgency. [2008.03]

The MATRIX study: evaluating the data in older adults. [2008.03]

The effects of anticholinergic drugs on attention span and short-term memory skills in children. [2008]

Do holding exercises or antimuscarinics increase maximum voided volume in monosymptomatic nocturnal enuresis? A randomized controlled trial in children. [2007.11]

Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. [2007.11]

The effects of anticholinergic drugs on attention span and short-term memory skills in children. [2007.09.07]

Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. [2006.10]

Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. [2006]

High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. [2005.09.25]

Trospium chloride for the treatment of overactive bladder with urge incontinence. [2005.05]

Effects of behavioral and drug therapy on nocturia in older incontinent women. [2005.05]

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. [2005.05]

Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. [2005.02]

A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. [2005]

Other research related to Ditropan (Oxybutynin)

Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. [2011.11.17]

Risk of serious falls associated with oxybutynin and tolterodine: a population based study. [2011.10]

Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea. [2011.09]

Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. [2011.09]

Oxybutynin for treatment of nocturnal enuresis in children. [2011.05]

Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, showering, sunscreen and person-to-person transference. [2011]

Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. [2011]

[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [Article in Chinese] [2011]

Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusor overactivity. [2010.12]

Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms. [2010.08]

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [2010.08]

Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. [2010.08]

Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. [2010.07.31]

Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusor overactivity. [2010.07.14]

Gelnique (oxybutynin chloride) 10% gel for overactive bladder. [2010.07]

Oxybutynin topical and transdermal formulations: an update. [2010.06]

Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. [2010.05]

Efficacy of combined oral-intravesical oxybutynin hydrochloride treatment for patients with overactive detrusors and indwelling urethral catheters. [2010.03]

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. [2010]

Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review. [2009.10]

Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. [2009.09]

[Effect of sublingual oxybutynin in postoperative pain after radical retropubic prostatectomy] [2009.09]

Effect of long-term oxybutynin administration on c-Fos expression in spinal neurons: inhibition of antimuscarinics on bladder afferents in conscious rats. [2009.01]

Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. [2009.01]

Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. [2009]

Transdermal oxybutynin. [2009]

Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs. [2008.11]

Fixed drug eruption to oxybutynin. [2008.09]

Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. [2008.08]

A Prospective, Randomized, Double-Blinded Placebo-Controlled Comparison of Extended Release Oxybutynin Versus Phenazopyridine for the Management of Postoperative Ureteral Stent Discomfort. [2008.03.11]

Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. [2008.03.11]

Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease? [2008.03]

Oxybutynin effects on Staphylococcus epidermidis biofilm production. [2008.03]

Evolution of transdermal oxybutynin in the treatment of overactive bladder. [2008.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017